Summary A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC). In untreated patients 25/38 (68%) with localized SCLC had raised blood levels of NSE (>13 ng ml-1), in extensive disease 34/39 (87%) patients had raised NSE levels. In patients with non-small cell lung cancer (NSCLC) the serum levels were raised in 16/94 (17%). In extensive tumours of non-pulmonary origin NSE levels were increased in 24/116 (20%) patients. Longitudinal studies indicated a good correlation between the response to chemotherapy and fall of NSE levels. Tumour progression was accompanied by a rising NSE in 25/29 patients, with doubling times of 7-90 days. In patients with progression with a normal NSE the recurrence was a NSCLC. Cerebral metastases occurring as the only recurrence during clinical complete remission were not accompanied by a rise of NSE. Serum NSE levels provides a valuable monitor for SCLC during and after chemotherapy.
Enolase is a glycolytic enzyme [EC 4.2.1.11] that is composed of sub units a, ,B & y. Neuron specific enolase [NSE] is the yy dimer of enolase (Marangos et al., 1979) . There is growing evidence that the histochemical demonstration of immunoreactive neuron specific enolase (NSE) in tumour cells can be used as an indicator of their likely neural or neuroendocrine origin. Biochemically these cells are characterised as possessing amine precursor uptake and decarboxylation (APUD) enzyme systems and the production of various hormones and peptides.
Tumours arising from the neuroendocrine cell system that contain NSE include, small cell lung cancer (SCLC) (Marangos et al., 1982; Sheppard et al., 1984; Springhall et al., 1984 ) and some comparative rare cancers such as neuroblastoma (Odelstad et al., 1982; Tsokos et al., 1984; Zeltzer et al., 1983) pancreatic islet cell cancers (Simpson et al., 1984; Lloyd et al., 1984) carcinoid tumours (Sheppard et al., 1984) and medullary thyroid carcinoma (Lloyd et al., 1983) . Several immunoassay methods have been described for NSE in body fluids. The results of assays of serum NSE using the radioimmunoassay (RIA) devised by Marangos and his colleagues have been published for several types of tumours of neuroendocrine origin Prinz et al., 1983; Zeltzer et al., 1983) . Other assays include further RIAs (Pahlman et al., 1984; Royds et al., 1984) including assays depending on the cross reactivity of an anti- rat NSE antiserum and human NSE (Kato et al., 1983) , or anti-mouse NSE and human NSE (Akoun et al., 1985) and immunobioluminescence assays (Wevers et al., 1983; Gerbitz et al., 1984) .
Small cell lung cancer is the commonest type of tumour showing neuroendocrine differentiation.
The measurement of serum NSE has shown to be of value in monitoring SCLC Pahlman et al., 1984; Esscher et al., 1985; Kato et al., 1983; Akoun et al., 1985; Ariyoshi et al., 1983; Johnson et al., 1984) .
Recently Pharmacia, Sweden have introduced a radioimmunoassay which provides the opportunity for a wide based large scale assessment of the role of NSE measurements in oncology. This paper describes an evaluation of the Pharmacia NSE-RIA assay in the assessment and monitoring of SCLC.
Materials and methods
Patients One hundred and seventy one patients with lung cancer were examined at presentation before treatment. They included 77 SCLC and 94 non-small cell carcinoma of the lung (NSCLC) (11 adeno-69 squamous, and 15 large cell). Patients were staged as having limited disease (disease confined to one hemithorax and mediastinal lymphnodes) or extensive disease (any spread outside these regions).
Various control groups were examined includingintestinal disease, 20 bronchopneumonia, 14 patients with benign lesions of the lung that were considered as possible lung cancers prior to biopsy and 10 patients with lung metastases from distant sites. Longitudinal studies were made of specimens obtained from 37 patients with SCLC, 19 from the start of treatment, and 18 commenced at various times after initiating chemotherapy. The follow up period was 4-28 months (average 10.5 months) with the sampling generally every 4-6 weeks according to the treatment protocol. The total samples per patient varied from 6 to 19. Thirty three patients were treated with CAVP (Cyclophosphamide 1000 mg m-2 day 1 i.v. Adriamycin 45 mg m-2 day 1 i.v., VP 16:213 lOOmgm-2 days 1, 3 and 5 i.v.) repeated every 3 weeks. In these studies commenced in 1982, samples of heparin plasma had been stored at each visit to the clinic. A further four patients were studied longitudinally, three were treated with ifosfamide, VP 16:213 and vincristine, and one received radiotherapy alone; in these patients serum was measured.
The serum and heparin plasma samples were stored at -20°C prior to analysis. Haemolysed samples were not used as they could be a source of a false elevation of NSE (Pahlman et al., 1984 , Johnson et al., 1984 .
An estimate of the inflammatory response to the combined effects of tumour tissue destruction and infection was obtained from the serum C-reactive protein (CRP) level measured by radial immunodiffusion.
The Pharmacia NSE RIA test is a double antibody radio-immunoassay. NSE in the sample competes with a fixed amount of 125I-labelled NSE for the binding sites of the specific antibodies (present in limited amount). Bound and free NSE are separated by the use of a second antibody covalently bound to spherical particles of agarose. After addition of the agarose antibody derivative, the mixture is centrifuged. The supernatant with the free NSE is then separated from the agarose pellet containing the bound NSE by decanting. The removal of the liquid phase can be done quantitatively and without extra washing. The radioactivity in the pellet is then measured. It is inversely proportional to the quantity of NSE in the sample. The detection limit is <2.6ngml-1, the measuring range 3.2-260ngml-1 with an average analysis time of 6 h for a batch of 40 samples. The suggested upper limit of normal is 12.5 ng mlP . ."
Results
Squamous SCLC Benign Metastatic tumours in the lung (10) 8 (80) 2 (20) Benign lesions of lung (11) 10 (91) 1 (9) Bronchopneumonia (20) 13 (65) 6 (30) 1 (5) Benign gastrointestinal and liver disease (45) 38 (84.4) eventually shown to be benign and 9.4ngml-' in bronchopneumonia. In 10 patients with lung metastases, from a variety of primary tumours, the median level was 5.6 ng ml-1, and all were < 15 ng ml '.
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Longitudinal studies Several patterns of response could be recognised, these were identified in the 23 patients who were studied from presentation the rarest being persistently high NSE after giving chemotherapy; 2 out of 23 (8.6%) of cases observed from presentation demonstrated this pattern. More commonly the NSE level gradually fell to reach a plateau after 2-6 courses of chemotherapy. In 4 patients the level fell to normal after a single course of chemotherapy. Several patients showed oscillating levels initially during the first few courses of treatment, NSE levels subsequently reached a low plateau. An example of the rapid fall patterns is shown in Figure 2 , the gradual decline of NSE during chemotherapy is shown in Figure 3 . The patient treated by radiotherapy alone had an NSE that fell from 40ngml-1 to 7.Ongml'-within 1 month of treatment. Nine patients including the 4 who responded rapidly were judged as being in complete remission after ending their chemotherapy, they were then followed for 6-22 months. Six out of 68 NSE (8.8%) measurements in these patients were unexpectedly high on a single occasion but the subsequent observations were all <15 ng ml-1 whilst the patients remained in clinical complete remission.
In 8 patients who developed brain metastases at a time when the disease had been in clinical remission the NSE levels remained normal.
Twenty-five out of 29 patients (15 of whom had been followed from presentation) who were progressive disease without a concomitant rise of NSE.
The serial measurement of CRP did not provide a sensitive tumour marker, but confirmed that the NSE levels were unaffected by infection.
Discussion
A raised serum NSE or heparin plasma (>13ngml-') as assayed by the Pharmacia NSE-RIA was observed in 77% of patients with SCLC at presentation. A comparison of the present data with published series is shown in Table II . Showing that the test gives results similar to those reported using a variety of immunoassays for NSE. Large cell undifferentiated lung cancers, which may be confused with SCLC are shown to have high NSE levels in this study and by Ariyoshi et al. (1983) and Pahlman et al. (1983) . Therefore a higher cut off value than in the present study would seem advisable when using the test to indicate that a tumour may be a SCLC in those cases where the biopsy was equivocal, technically unsatisfactory or (17) unobtainable. In such a case NSE levels >25 ng ml-1, are highly suspicous but not an infallible diagnostic indicator of SCLC. Treatment of SCLC by chemotherapy was followed by a decrease of NSE when it had been raised at presentation to reach normal levels when there was clinical evidence of an objective remission. By contrast the levels in patients who only had stable disease or failed to respond to treatment did not normalise. The NSE level was unaffected by the presence of cerebral metastases if they were the solitary site of progression of the disease. All patients except four who had progressive disease had an exponential rise of NSE, which could even be detected as it commenced its rise through the normal range. Retrospectively, the interval between the first rise of NSE and the clinical detection of progression varied from 0-112 days (median 42, n=14) . This data supports the report of Johnson et al. (1984) who showed a persistently raised NSE level in 15 out of 23 (65%) patients 2-12 weeks (median 4) before clinical recognition of recurrence. It is of interest that 3 of the patients, who showed progressive disease without a rise of NSE, had histologically proven NSCLC. This indicates that normal NSE levels in a case of progressive disease warrant further investigation of the nature of the recurrent tumour. The relationship between tumour mass and NSE and response to treatment seen in the present study is comparable to that reported by Carney et al. (1982) ; Ariyoshi et al. (1983; 1984) ; Pahlman et al. (1984) ; Johnson et al. (1984) and Akoun et al. (1985) .
Immunochemical assays for NSE either use an antisera to human yy enolase (NSE) or depend on the cross reactivity of anti rat yy enolase (Kato et al., 1983) or anti mouse yy enolase (Akoun et al., 1985) antisera with human NSE. However, it is evident that the serum contains a mixture of the yy form of enolase and ocy hybrid molecules that cross react with the antisera to yy enolase. Gerbitz et al. (1984) have estimated that the serum concentrations in healthy subjects of the ay and yy enolase were 6.0 + 3.2 and 3.3 + 1.5 ng ml-1 respectively. Kato et al. (1983) 
